These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 33197449)

  • 41. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability?
    Chiu CW; Tsai PJ; Lee CC; Ko WC; Hung YP
    J Microbiol Immunol Infect; 2021 Dec; 54(6):1011-1017. PubMed ID: 34229970
    [TBL] [Abstract][Full Text] [Related]  

  • 42. AsnB is responsible for peptidoglycan precursor amidation in
    Ammam F; Patin D; Coullon H; Blanot D; Lambert T; Mengin-Lecreulx D; Candela T
    Microbiology (Reading); 2020 Jun; 166(6):567-578. PubMed ID: 32375990
    [No Abstract]   [Full Text] [Related]  

  • 43. Therapeutic Effects of Bifidobacterium breve YH68 in Combination with Vancomycin and Metronidazole in a Primary Clostridioides difficile-Infected Mouse Model.
    Yang J; Meng L; Yang H
    Microbiol Spectr; 2022 Apr; 10(2):e0067222. PubMed ID: 35311540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of
    Bassères E; Eubank TA; Begum K; Alam MJ; Jo J; Le TM; Lancaster CK; Gonzales-Luna AJ; Garey KW
    Antimicrob Agents Chemother; 2024 Mar; 68(3):e0162123. PubMed ID: 38364016
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection.
    Roder C; Athan E
    Drugs R D; 2020 Sep; 20(3):209-216. PubMed ID: 32377889
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antimicrobial susceptibility of Clostridioides difficile isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveillance study from 2013 to 2017.
    Karlowsky JA; Adam HJ; Baxter MR; Dutka CW; Nichol KA; Laing NM; Golding GR; Zhanel GG
    J Antimicrob Chemother; 2020 Jul; 75(7):1824-1832. PubMed ID: 32294172
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection.
    Abutaleb NS; Seleem MN
    Sci Rep; 2021 Mar; 11(1):7093. PubMed ID: 33782498
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin.
    Yamaguchi T; Konishi H; Aoki K; Ishii Y; Chono K; Tateda K
    J Infect Chemother; 2020 May; 26(5):483-491. PubMed ID: 32165071
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Clostridium difficile Lineage Endemic to Costa Rican Hospitals Is Multidrug Resistant by Acquisition of Chromosomal Mutations and Novel Mobile Genetic Elements.
    Ramírez-Vargas G; Quesada-Gómez C; Acuña-Amador L; López-Ureña D; Murillo T; Del Mar Gamboa-Coronado M; Chaves-Olarte E; Thomson N; Rodríguez-Cavallini E; Rodríguez C
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137804
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanisms and impact of antimicrobial resistance in Clostridioides difficile.
    Dureja C; Olaitan AO; Hurdle JG
    Curr Opin Microbiol; 2022 Apr; 66():63-72. PubMed ID: 35077947
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy Assessment of the Co-Administration of Vancomycin and Metronidazole in
    Zhong S; Yang J; Huang H
    J Microbiol Biotechnol; 2024 Apr; 34(4):828-837. PubMed ID: 38668685
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The molecular characters and antibiotic resistance of Clostridioides difficile from economic animals in China.
    Zhang WZ; Li WG; Liu YQ; Gu WP; Zhang Q; Li H; Liu ZJ; Zhang X; Wu Y; Lu JX
    BMC Microbiol; 2020 Mar; 20(1):70. PubMed ID: 32228454
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Are Vancomycin Non-Susceptible Clostridioides difficile Strains Emerging?
    Lutgring JD; McKay SL; Gargis AS; Halpin AL; McDonald LC
    Clin Infect Dis; 2022 Oct; 75(9):1677-1678. PubMed ID: 35818797
    [No Abstract]   [Full Text] [Related]  

  • 54. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.
    Crowther GS; Baines SD; Todhunter SL; Freeman J; Chilton CH; Wilcox MH
    J Antimicrob Chemother; 2013 Jan; 68(1):168-76. PubMed ID: 22966180
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clostridium difficile bacteremia, Taiwan.
    Lee NY; Huang YT; Hsueh PR; Ko WC
    Emerg Infect Dis; 2010 Aug; 16(8):1204-10. PubMed ID: 20678312
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fidaxomicin for the treatment of
    Skinner AM; Scardina T; Kociolek LK
    Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Two case reports of Clostridium difficile bacteremia, one with the epidemic NAP-1 strain.
    Hemminger J; Balada-Llasat JM; Raczkowski M; Buckosh M; Pancholi P
    Infection; 2011 Aug; 39(4):371-3. PubMed ID: 21509425
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clostridioides difficile Biofilm.
    Vuotto C; Donelli G; Buckley A; Chilton C
    Adv Exp Med Biol; 2024; 1435():249-272. PubMed ID: 38175479
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular Epidemiology and Risk Factors of
    Yang Z; Huang Q; Qin J; Zhang X; Jian Y; Lv H; Liu Q; Li M
    Front Cell Infect Microbiol; 2020; 10():578098. PubMed ID: 33425775
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.
    Shah D; Dang MD; Hasbun R; Koo HL; Jiang ZD; DuPont HL; Garey KW
    Expert Rev Anti Infect Ther; 2010 May; 8(5):555-64. PubMed ID: 20455684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.